Notably, two such trials with low dose NAC, 600 mg/day over 3 years demonstrated some efficacy in inhaled corticosteroid (ICS)-nave patients only ( High-dose NAC (1,200 mg/day) showed superior outcomes, improving lung volumes [Forced Vital Capacity (FVC), Residual Volume/ Total Lung Capacity (RV/TLC), Inspiratory Capacity (IC)] and exercise tolerance( 2575% ), reactance at 6 Hz, and resonant frequency over 1 year, while these declined with placebo ( The PANTHEON trial, a large double-blind RCT in GOLD defined COPD patients with severe airflow obstruction and a history of 2 COPD exacerbations in the previous year, found that NAC 600 mg BID reduced exacerbation rates in NAC group (497 acute exacerbations in 482 patients, 1.16 AcEx/pt/yr) versus placebo (641 acute exacerbations in 482 patients, 1.49 AcEx/Pt/yr), p 1 log 10 ) compared to untreated controls ( in vitro study on blood cells of patients with Type 2 Diabetes Mellitus (DM) and healthy volunteers showed that NAC has anti-TB microbial properties on its own and significantly inhibited the growth of MTB as compared to sham treated media by about 50% at 8 days and 70% at 15 days, respectively
%201295%20and%20Ipamorelin%20(Growth%20Hormone%20Secretagogue)%20and%20how%20can%20they%20be%20minimized%3F)
With a longer half-life than natural IGF-1, IGF-1 LR3 enhances lean muscle mass growth by stimulating satellite cell activation, promoting hyperplasia (the creation of new muscle fibers), and increasing protein synthesis
it does not establish that any schedule is safe or effective in a living subject, and none of it should be read as a protocol to follow
T.BalasubramanyamA.et al
One study found that direct recombinant IGF-1 LR3 administration at days 2, 5, and 7 accelerated muscle healing in mice with strain-injured muscles [1]
